# Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

> **NCT00697099** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 2326 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Semuloparin sodium
- **DRUG:** Enoxaparin sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00697099
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 2326 (ACTUAL)
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697099, "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00697099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*